Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "f hoffmann la roche ltd"

Roche launches new fertility test for ovarian reserve assessment

F. Hoffmann-La Roche Ltd has launched the new Elecsys Anti-Mullerian Hormone, or AMH, blood test, a fertility test for assessing a woman's ovarian reserve. The AMH blood test can be measured during any day of the menstrual cycle and is a superior ..., 6 days ago

10 images for f hoffmann la roche ltd

ABC News 4 Charleston, 1 week ago
Sys-Con Media, 1 week ago
I Stock Analyst, 1 week ago
On Office, 1 month ago, 2 months ago
PR inside, 5 months ago
Scottrade, 3 months ago
Bioresearch Online, 4 months ago
ABC News 4 Charleston, 5 months ago
I Stock Analyst, 5 months ago

Roche announces resignation of board member

F. Hoffmann-La Roche Ltd has announced the resignation of Arthur Levinson from the board of directors. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as CEO at Calico. "I would like to thank Art for ...
 Individual.com3 weeks ago

Breast Cancer Drug Perjeta Shows 'Unprecedented' Success In Clinical Trials

Image Credit: 2014 F. Hoffmann-La Roche Ltd Chuck Bednar for Your Universe Online Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche , has shown unprecedented success in extending the lives of ...
 Red Orbit3 days ago Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis  Market Pulse Navigator2 weeks ago Global Transcriptomics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and Thermo Fisher Scientific  Sys-Con India1 week ago Depression Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015  Individual.com2 hours ago

Chugai Pharma launches ant-cancer agent Alecensa capsules

Chugai Pharmaceutical, a subsidiary drug manufacturer operating in Japan controlled by HoffmannLa Roche, has launched the ALK inhibitor Alecensa capsule 20mg and 40mg (alectinib hydrochloride) for the indication of ALK fusion gene positive ...
 PharmaBiz3 weeks ago Chugai Pharmaceutical launches non-small cell lung cancer drug  Individual.com2 weeks ago

New Clinical Trials and Studies Study Results Reported from F. Hoffmann-La Roche (The use of phase 2 interim analysis to expedite drug development...

New Clinical Trials and Studies Study Results Reported from F. Hoffmann-La Roche (The use of phase 2 interim analysis to expedite drug development decisions) By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators discuss ...
 4 Traders3 weeks ago Occlusive Arterial Disease Clinical Trials Market 2014 Analysis in a New Report Available at  Wall Street Select1 day ago Atherosclerosis Global Clinical Trials Review, H2, 2014 - New Report Available  RCL Advisors1 week ago

Patent Issued for Dual Modulators of 5HT.Sub.2A and D.Sub.3 Receptors

By a News Reporter-Staff News Editor at Biotech Week Hoffmann-La Roche Inc. (Nutley, NJ) has been issued patent number 8829029, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors (see also Pharmaceutical ...
 Pharmacy Choice1 week ago

POCT Market in China 2014-2018

FEATURED COMPANIES Abbott Laboratories Bayer HealthCare Bioptik Technology F. Hoffmann-La Roche Fudakang Ind'l LifeScan MORE About POCT POCT, also called near-patient ...
 Research and Markets1 week ago Genomics Market in the US 2014-2018  Research and Markets1 week ago

Garford Pty Ltd v Dywidag-Systems International Pty Ltd [2014] FCA 1039

FEDERAL COURT OF AUSTRALIA Garford Pty Ltd v Dywidag -Systems International Pty Ltd [2014] FCA 1039 Citation: Garford Pty Ltd v Dywidag -Systems International Pty Ltd [2014] FCA 1039 Parties: GARFORD PTY LTD v DYWIDAG ...
 Federal Court of Australia3 days ago

CHUGAI PHARMACEUTICAL : -Bisphosphonate Antiresorptive Agent, Ibandronate Sodium Hydrate Oral Agent, Demonstrates Efficacy in Osteoporosis in Phase III Trial

Release date- 22092014 - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo ; Chairman & CEO: Osamu Nagayama (hereafter, 'Chugai')] and Taisho Pharmaceutical Co., Ltd. [Head Office: Toshima-ku, Tokyo ; President: Shigeru Uehara (hereafter, ...
 4 Traders1 week ago CHUGAI PHARMACEUTICAL : Launch of the Anti-Cancer Agent / ALK Inhibitor Alecensa┬«  4 Traders3 weeks ago Chugai Debuts on Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment  TMC Net1 week ago Bisphosphonate antiresorptive agent, ibandronate sodium hydrate oral agent, demonstrates efficacy in osteoporosis in phase III trial  PharmaBiz1 week ago

Growing Patient Pool and Favorable Regulations Spur the Global Market for Pediatric Drugs and Vaccines, According to New Report by Global Industry Analysts, Inc.

PRWeb Demand for pediatric drugs and vaccines is growing in sync with the increasing birth rate, and the rising incidence and prevalence of various disease and disorders among children across the globe. Historically, the market for pediatric drugs ...
 Market Pulse Navigator1 day ago Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc.  Stock Nod1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less